| Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial M Weller, N Butowski, DD Tran, LD Recht, M Lim, H Hirte, L Ashby, ... The Lancet Oncology 18 (10), 1373-1385, 2017 | 949 | 2017 |
| Lon protease preferentially degrades oxidized mitochondrial aconitase by an ATP-stimulated mechanism DA Bota, KJA Davies Nature cell biology 4 (9), 674-680, 2002 | 626 | 2002 |
| First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma LM Liau, K Ashkan, DD Tran, JL Campian, JE Trusheim, CS Cobbs, ... Journal of translational medicine 16, 1-9, 2018 | 532 | 2018 |
| Deep-learning convolutional neural networks accurately classify genetic mutations in gliomas P Chang, J Grinband, BD Weinberg, M Bardis, M Khy, G Cadena, MY Su, ... American Journal of Neuroradiology 39 (7), 1201-1207, 2018 | 401 | 2018 |
| Modulation of Lon protease activity and aconitase turnover during aging and oxidative stress DA Bota, H Van Remmen, KJA Davies FEBS letters 532 (1-2), 103-106, 2002 | 288 | 2002 |
| Downregulation of the human Lon protease impairs mitochondrial structure and function and causes cell death DA Bota, JK Ngo, KJA Davies Free Radical Biology and Medicine 38 (5), 665-677, 2005 | 243 | 2005 |
| Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 … LM Liau, K Ashkan, S Brem, JL Campian, JE Trusheim, FM Iwamoto, ... JAMA oncology 9 (1), 112-121, 2023 | 175 | 2023 |
| Clinical practice experience with NovoTTF-100A™ system for glioblastoma: the Patient Registry Dataset (PRiDe) MM Mrugala, HH Engelhard, DD Tran, Y Kew, R Cavaliere, JL Villano, ... Seminars in oncology 41, S4-S13, 2014 | 149 | 2014 |
| Interstitial chemotherapy with biodegradable BCNU (Gliadel®) wafers in the treatment of malignant gliomas DA Bota, A Desjardins, JA Quinn, ML Affronti, HS Friedman Therapeutics and clinical risk management 3 (5), 707-715, 2007 | 146 | 2007 |
| Mitochondrial Lon protease in human disease and aging: Including an etiologic classification of Lon-related diseases and disorders DA Bota, KJA Davies Free Radical Biology and Medicine 100, 188-198, 2016 | 145 | 2016 |
| Cisplatin-induced mitochondrial dysfunction is associated with impaired cognitive function in rats N Lomeli, K Di, J Czerniawski, JF Guzowski, DA Bota Free Radical Biology and Medicine 102, 274-286, 2017 | 143 | 2017 |
| Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier K Di, GK Lloyd, V Abraham, A MacLaren, FJ Burrows, A Desjardins, ... Neuro-oncology 18 (6), 840-848, 2016 | 141 | 2016 |
| Protein degradation in mitochondria: implications for oxidative stress, aging and disease:: a novel etiological classification of mitochondrial proteolytic disorders DA Bota, KJA Davies Mitochondrion 1 (1), 33-49, 2001 | 133 | 2001 |
| Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy X Gong, PH Schwartz, ME Linskey, DA Bota Neurology 76 (13), 1126-1134, 2011 | 123 | 2011 |
| Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): results of a double-blind randomized phase II trial DA Reardon, A Desjardins, JJ Vredenburgh, DM O'Rourke, DD Tran, ... Clinical Cancer Research 26 (7), 1586-1594, 2020 | 121 | 2020 |
| Low-doses of cisplatin injure hippocampal synapses: a mechanism for ‘chemo’brain? AL Andres, X Gong, K Di, DA Bota Experimental neurology 255, 137-144, 2014 | 110 | 2014 |
| Non-viral precision T cell receptor replacement for personalized cell therapy SP Foy, K Jacoby, DA Bota, T Hunter, Z Pan, E Stawiski, Y Ma, W Lu, ... Nature 615 (7953), 687-696, 2023 | 109 | 2023 |
| Effect of vocimagene amiretrorepvec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma: a … TF Cloughesy, K Petrecca, T Walbert, N Butowski, M Salacz, J Perry, ... JAMA oncology 6 (12), 1939-1946, 2020 | 102 | 2020 |
| TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth K Di, ME Linskey, DA Bota Oncogene 32 (42), 5038-5047, 2013 | 99 | 2013 |
| Management of low-grade glioma: a systematic review and meta-analysis TJ Brown, DA Bota, MJ van Den Bent, PD Brown, E Maher, D Aregawi, ... Neuro-oncology practice 6 (4), 249-258, 2019 | 93 | 2019 |
Naomi Lomeli, PhDUniversity of California, IrvineVerified email at uci.edu
